BLTE
BELITE BIO, INC
NASDAQ · Healthcare · Biotechnology · US
$170.96
+0.36%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$170.86
From 52W high−11.70%
Volume90690.00
Market cap$6.88B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$170.86
From 52W high
−11.70%
Volume
90690.00
Market cap
$6.88B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−60.3x
P/E (TTM)
—
RSI (14)
51.6
MomentumView details →
1D Return
+0.36%
YTD Return
+6.12%
SummaryUpdated Jun 1, 2026
Belite Bio, Inc (NASDAQ:BLTE) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Diego, California. The company operates as a subsidiary of Lin Bioscience International Ltd and went public in April 2022. Belite Bio specializes in developing novel oral therapeutics for rare retinal diseases, particularly focusing on conditions that cause progressive vision loss and blindness. The company's primary focus is on advancing treatments for Stargardt disease and geographic atrophy, two debilitating eye conditions that currently have limited or no approved treatment options.
Similar companies
Latest newsMore news →
Belite Bio CFO and Director Chuang Hao-Yuan sold 62,395 American depositary shares for approximately $12.8 million on September 4 and September 8, 2026, under a Rule 10b5-1 trading plan.10d agoBelite Bio submitted a New Drug Application to Japan's Ministry of Health, Labour and Welfare under the Sakigake designation system for tinlarebant to treat Stargardt disease type 1.12d agoThe U.S. Food and Drug Administration accepted and granted Priority Review designation to Belite Bio's New Drug Application for tinlarebant for the treatment of Stargardt Disease Type 1, with a PDUFA date set for February 12, 2027.40d ago